A partnership between Alliance and Opus Genetics aims to advance gene therapy development and seeks IND filing with the FDA.
1 report, 1 independent
Updated Jul 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A partnership between Alliance and Opus Genetics aims to advance gene therapy development and seeks IND filing with the FDA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Opus Genetics plans to submit an application to the FDA.Sub-event
The partnership aims to advance gene therapy development and seeks IND filing with the FDA.1 source
Keep exploring
The entities involved
Related events
- Zenith collaborates with Harvard researchers on clinical studies, receiving FDA clearance for the trial.
- uniQure N.V. traded on the Nasdaq stock exchange and submitted a Biologics License Application (BLA) for accelerated approval of its gene therapy.
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
- Canandaigua National Trust Co of Florida bought a new stake in AbbVie shares and granted Breakthrough Therapy Designations for one of its drugs.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
Coverage
Newest first; wire copies grouped- GlobeNewswireOpus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness Collaboration aims to accelerate development of OPGx-RDH12, a gene therapy for RDH1